retatrutide 2025 trial results This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond Eli Lilly's Phase 3 data

Received: Mar 18, 2025

Rotating injection sites with each dose reduces their frequency and severity

A pesar de la baja incidencia de estos eventos adversos y de la probabilidad de que los beneficios superen estos riesgos en los individuos con obesidad grave, los mdicos y los pacientes deben ser conscientes de estos efectos secundarios graves

[ Editor's note: After MH went to press, Jelly clarified that he did briefly try weight-loss meds very early on his journey, but stopped after two weeks.] We talked for several hours at intervals over the course of this year about how he was doing it, and how he did it

In a clinical trial, adults who switched from high-dose injectable obesity drugs to oral GLP-1 pill Foundayo were able to maintain most of their previous weight loss over 1 year, with relatively limited weight regain

Among the tissues and organs crucial in regulating glucose and lipid metabolism, pancreas, brain, and adipocytes express GIP receptors (GIPRs), while pancreas, brain, and gastrointestinal tract are rich in GLP-1 receptors (GLP-1Rs) (40)